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DR. RADFORD (Univ. Pittsburgh): This year we
have a slight departure from the first Sympo-
sium. Since one of the aims of this Symposium
deals with the question of regulations and stan-
dards, we have asked representatives of various
Federal agencies to provide insights from their
standpoints.
DR.VILMAR. HUNT(U.S. EPA): We have had in
this session a juxtaposition of several very
troublesome issues that face regulatory agencies
inparticular andthe public's concerns in general.
I would like to comment briefly on some ofthese
issues that relate to the presentations. First, in
terms ofthe clear exposition by Dr. Lilienfeld on
the limitations of the epidemiologic approach to
evaluating the impact on human health of envi-
ronmental and occupational contaminants, we
are nowable to see thatthe nexus ofepidemiology
concerns has been shifting, albeit slowly over the
years. We can see quite clearly that we have
generated many hypotheses relating agents to
disease. But we are now in a regulatory environ-
ment, with expectations from the public at large
that they will not be inordinately regulated on
the one hand, but also that they will be protected
against risks which are ofvariable and uncertain
importance-a paradox.
Given the linkage, then, between the first pre-
sentation and the second, by Dr. Dietz, of the
toxicological parameters now clearly influencing
the direction in which epidemiology can go, we
are seeing a new linkage between the previous
descriptive epidemiologic studies and more useful
analytical investigations possible today, and how
indeedthey may be linked to more critical assess-
ments that toxicologic research has opened up.
Both epidemiology and toxicology have been re-
sponding these last several years to demands of
the regulatory environment, with much closer
quality control ofdata, and more critical evalua-
tion ofthe adequacy ofdata that comes to hand.
This session's papers suggest a reassessment and
a rearrangement of information from the toxico-
logic world into the epidemiologic world. To com-
ment on Dr. Dietz' nice set ofcircles in which he
was able to put risk assessment as the focal point
and surround it by carcinogenic bioassay, phar-
macokinetics and macromolecular components,
one must visualize that with three circles over-
lapping, there are seven spaces inthat setofthree
circles and Dr. Dietz chose to fill four ofthem. The
other three could well be filled by such topics as
descriptive or analytic epidemiology or clinical
case studies. I also sense, from the interaction
with a variety of scientists who come my way, a
tension that appears between the toxicological
approach and the epidemiologic approach. They
are too often considered as separate approaches.
We are startingto see a good linkage andbetween
these two approaches.
As I listened to the third paper, I was struck by
the growing complexity of the issues that are
being inserted into risk assessment attempts. We
recognize the different viewpoints that everybody
brings to the issue of risk assessment, whether
they are looking at it from a scientific point of
view, a personal point of view, a policy point of
view, or whatever. For example, another complex
issue which has epidemiologic considerations is
the abortion issue. As it rages in the next several
months, one will be able to see a complicated view
of risk assessment, as arguments flow between
scientists, legislators and the public on this issue,
especially the women affected. Ifone has followed
the issue of maternal mortality and infant mor-
tality from the last century, one is aware of the
difficulties ofdeveloping a sensitive epidemiologic
approach to reproductive hazards. You can well
see the public policy issue for risk assessment.
Eliminating all opportunities for abortion brings
the ultimate risk of the sexual act itself to the
woman who is involved. A recent Supreme Court
decision commented that the teenage girl had the
highest risk ofhaving an adverse effect in terms
ofher sexual activity, in contrast with the male.
When we look at the epidemiologic consider-
ations of reproductive risks from occupational
andenvironmental contaminants, we can see that
the changing fashion of abortion in this country
and in others has had a remarkable effect on
maternal and infant morbidity and mortality.
There was a time about 10 years ago or so, when
the largest proportion of use of hospital beds in
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women having undergone abortions with medical
complications. In this country the situation has
changed. Nowwehave difficultproblems indevel-
oping epidemiologic studies to deal with an end
point which varies depending on whether the
progress of a pregnancy involves a selective or
nonselective factor.
In terms of Dr. Kasperson's comments, for an
issue such as infant and maternal mortality and
its relationship to environmental and occupa-
tional exposures, epidemiologic evidence will be
difficult to obtain. A policy decision could be
made, or legislative action taken, that will
change the entire set of relationships of the
events to the environment inwhich it could occur.
My question is-are the complexities of the
models being used for risk assessment going to
help or hinder the development ofmore sophisti-
cated and sensitive approaches to our epidemio-
logic responsibilities, which are especially impor-
tant in the whole reproductive area right now?
DR. RADFORD: YOU mentioned, Dr. Kasperson,
that radiation risks are higher in women than
they are in men, when one considers carcinogenic
and teratogenic effects. It strikes me this is a case
where animal models are able to be helpful in
some ways but not in others. I will ask the ques-
tion: Shouldn't this sensitive subsetofthe popula-
tion, namely the women, be considered the most
important group to protect and if so, how do you
take this into account in standard-setting?
DR. R. E. KASPERSON (Clark Univ.): I gather
already there is some increased protection for
women as opposed to men in radiation standards.
Since you are the expert, I will defer to you on
that. But isn't it true that there are some areas of
protection right now that are in fact different?
DR. RADFORD: No.
DR. KASPERSON: Well, it may be during preg-
nancy, for example.
DR. RADFORD: The most sensitive period during
pregnancy is the first trimester when a woman
very frequently doesn't know she is pregnant. It
is a very difficult question related to the whole
question of sexual mores. Is it the responsibility
of the woman to report a sexual act to her em-
ployer in order to be able to protect herself?
DR. HUM' Although the most vulnerable part
of the life cycle is the fetus at the first three
months ofpregnancy, I would also make an equal
period ofsensitivity to the sperm exposed to radi-
ation that fertilized the ovum, so that indeed any
man who is in the same radiation environment is
also at high risk, presenting to the woman an
imperfect sperm; this is equivalent to the sensi-
tivity of the embryo in the first three months.
This problem points to a difference in mores and
the attitude toward who is vulnerable. Our astro-
nauts, as Iunderstand it, leave theirfrozen sperm
back here on earth before they take off into the
radiation belt.
Sothere is aperceptionthat sperm are vulnera-
ble to radiation yet there tends to be less concern
in the initial phase before fertilization, as much
as there is once there is a fertilized ovum.
DR. RADFORD: Dr. Dietz, would you like to com-
ment on the question of animal models in this
situation?
DR. F. K. DIETZ (Dow Chemical USA): Yes,
although I didnotspecificallyrefertoradiation as
a causative agent. I think that one ofthe points I
was trying to make was that pharmacokinetic
data are highly desirable in working with animal
models ofchemically induced toxicity. Pharmaco-
kinetic concepts may be especially useful in in-
vestigating sensitivity differences between spe-
cies or sexes. Historically, it has not always been
possible to define relationships between concen-
tration and toxicity in animal models because of
limitations in available analytical methodology.
Consequently, in many studies the pharmaco-
kinetic fate of radioactivity derived from a ra-
diolabeled parent compound was often evaluated
rather than the fate of the compound per se.
However, with current analytical instrumenta-
tion and techniques, it is often possible to deter-
mine the pharmacokinetic fate of an unlabeled
chemical and/or its metabolites. This capability
enables a more critical inspection ofthe relation-
ship between concentration and toxicity in ani-
mal models.
One area ofinvestigation that I think promises
to be very exciting involves the use ofpharmaco-
kinetic concepts in evaluating a chemical's tera-
togenic and/or reproductive toxicity potential.
Simply because an animal is exposed to a com-
pound and at some point in time we see a terato-
genic effect is not always sufficient to explain
what is occurring within the animal from the
point ofview ofinternal dose ofthe toxicant, that
is, howmuch, how long and in what form does the
parent compound reach sensitive target areas?
Consequently, issues such as the effect of preg-
nancy on metabolism, placental metabolism, pla-
cental transfer and possible fetal metabolism are
all questions that can be addressed in animal
studies ofthis type oftoxicity, utilizing pharma-
cokinetic concepts.
DR. RADFORD: Dr. Kasperson, would you like to
say anything about the question of susceptible
subsets of populations in terms of deciding on
acceptable risk in general?
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DR. KASPERSON: With a more susceptible popu-
lation, such as women inthe case ofradiation, one
must balance alternative kinds ofgoals. The con-
flict in this case would be the freedom of the
individual to work and the jobs that would be
open to her. One could proceed by meeting the
balance ofissues either through trying to achieve
informed consent from the individual, or through
the regulatory approach. It is difficult to balance
which ofthese methods isthe more appropriate. It
may be that ifthe magnitude ofthe risk is suffi-
ciently great, one might want to use the regula-
tory mode, whereas in other kinds of situations
where the discrepancies in risk are not so great,
or, ifthe alternative values, such as the freedom
to work, are a major issue, to try to handle that in
a voluntary way on the part ofthe individual.
DR. PETER INFANTE (OSHA): I have one com-
ment and then one question. The comment is
regarding Dr. Lilienfeld's presentation. I was
very pleased to see him discuss the sensitivity of
one ofthe microwave studies. I think that all too
often we are extremely critical when studies show
adverse effects, as we should be, but, we do not
demonstrate this same amount ofcritical evalua-
tionwhen studies fail to show any adverse effect. I
think that, as members ofthe scientific andpublic
health community, we should be emphasizing the
sensitivity ofour studies and concern forthe error
of not finding an effect when in fact one may be
there.
I raise this point because, for example, I know
that for many ofthe substances which are struc-
tural analogs of vinyl chloride, at least half a
dozen epidemiologic studies have been conducted,
and all ofthese studies are extremely insensitive.
And yet, often they are cited as demonstrating
that the analogs ofvinyl chloride are not carcino-
genic to man when, in fact, we really don't have
information to evaluate their carcinogencity in
humans. That is not to say that the studies
shouldn'tbe done. However, sometimesthere sim-
ply are limitations in the amount ofdata that you
have available, the sample size, or the latency
characteristics of the population studied. So I
think that, from a public health standpoint, it is
extremely important to discuss sensitivity in any
study that is conducted.
The question I have is for Dr. Dietz. IfI under-
stood your presentation correctly, you mentioned
that for carcinogens that may require metabolic
activation to the ultimate carcinogen, the mouse
may be more sensitive than man because the
mouse has a higher metabolic rate or maybe a
higher rate ofalkylation. Nowby the same token,
ifcancer progression is due not only to mutation,
but also to effects on repair mechanisms, then
might not those same animals be able to repair
better than man? Consider this particularly in
light of the fact that humans are exposed to
numerous toxic materials in their work environ-
ment, or in the environment in general, as com-
pared to experimental studies which only address
the effect of one chemical at a time. I raise this
question because I know that in the past Perry
Gehringhad done modelingforvinyl chloride and
concluded that 50 ppm atmospheric concentration
was a threshold for the carcinogenicity of vinyl
chloride with regard to liver angiosarcoma.
Subsequent to that study, Dr. Maltoni induced
angiosarcoma of the liver in experimental ani-
mals at 25 ppm, and now, in fact, he has induced
mammary carcinomas and cancers of different
sites at between 1 and 5 ppm! Your modeling
seems very interesting, and I know that Dow is
doing a lot ofvery sophisticated work inthis area.
But when one sits back and tries to interpret
what this means to humans, given the number of
other substances to which workers and the gen-
eral public are exposed, and then one sees other
data bases that don't seem to be quite consistent
with the modeling, at this time, how does one
interpret the model? Just recently, Dow had done
a study on methylene chloride where the cancer
that was induced in the experimental animal was
salivary gland sarcomas rather than liver cancer,
which isthe sitewhere one mightexpect aneffect.
When one finds something that doesn't make
sense according to a metabolic model, what does
all this modeling mean? How does one really
interpret these results in terms of extrapolating
to humans?
DR. DIETZ: Before responding, let mepreface my
comments by stating that I am not familiar with
all of the toxicity data that exist for each of the
compounds you have referred to. Consequently, I
will try to address your questions in a generalized
rather than a compound-specific manner.
One ofyour early comments raised the issue of
species differences in DNA repair and how such a
difference might influence species sensitivities to
metabolically activated carcinogens. As indicated
in my presentation, the rate ofoxidative metabo-
lism in mammals is generally related to body
surface area. This suggests that in situations
where the ultimate toxicant is one which requires
metabolic transformation, small laboratory ro-
dents will activate these materials at a faster rate
than man. This assumes, ofcourse, that the same
metabolic pathways for bioactivation exist be-
tween the species ofinterest. On the assumption
that this production of a toxic metabolite is the
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mechanism responsible for interacting with DNA
or other critical macromolecular sites, it would be
logical to expect that the mouse would show a
greater degree of macromolecular interaction
than larger animal species by nature of its
greater metabolic rate. This brings us to your
question regarding species differences in DNA
repair and how this might influence species sensi-
tivities. Previous studies by Hart and Setlow in-
vestigating the effects ofUV irradiation on DNA
excision-repair in different species have shown
that man has a greater repair capability than
several other animals, including rats and mice.
This information, coupled with that regarding
species differences in rates of metabolic activa-
tion, suggests that man would be less sensitive
than smaller species since he not only has a lower
activation rate but is also able to repair DNA
damage to a greater degree. The statement assu-
mes, of course, that the metabolic processes be-
tween a mouse and man result inthe formation of
the same toxic metabolite(s) and that the mecha-
nisms oftoxicity, DNA repair and ultimate carci-
nogenicity are similar between the two species.
Another one of your questions made reference
to the state ofthe art in pharmacokinetic model-
ing as it applies to species extrapolation. In many
instances, pharmacokinetic modeling has utilized
a traditional format in which compartmental
analysis is used to evaluate the data. Although
compartmental analysis is rather simplistic from
a physiological point ofview it has been success-
fully utilized by us and others, including persons
in the pharmaceutical areas to predict the phar-
macokinetic data. This type ofmodeling is based
on the incorporation of physiological parameters
such as blood flow rates, etc., which reflect the
state of our body as being a physiological entity.
Several investigators, including Dr. Melvin An-
derson and his co-workers have utilized this mo-
deling technique in evaluating the pharmaco-
kinetic characteristics of various chemicals. I
foresee the use ofthis type ofmodeling as a means
by which we can further refine our analysis of
pharmacokinetic data and improve ourextrapola-
tion of toxicity data across different species. I
suppose that the bottom line regarding pharma-
cokinetic modeling and species extrapolation is
that we still make predictions regarding antici-
pated responses in man that are based on obser-
vations in animal models. These predictions are
going to be no better than the techniques utilized
in analyzing the data. As a consequence, we are
continually trying to refine our techniques using
the best methodology available.
DR. MAURICE SHAPIRO (Univ. Pittsburgh,
School ofPublic Health): I would like to ask Dr.
Lilienfeld a question. Would you care to comment
on the need for and the possibility of improving
upon death certificates, as well as medical histo-
ries ofindividuals, in view ofthe factthatfor such
an organized group as the Foreign Service, the
information that you had seemed to be inade-
quate?
I would also like to ask Dr. Kasperson a ques-
tion. If I heard you correctly, you said you were
more interested in avoiding risk than mitigating
risk. Would you care to comment on that?
DR. A. M. LILIENFELD (Johns Hopkins Univ.): I
think that every effort should be made to improve
death certificates in general, more specifically
with regard to cause of death statements. How-
ever, the basic issue is how much effort can be
expended in this direction on a national basis.
What is actually needed is a continuing surveil-
lance system ofvalidation of the accuracy of the
statement of cause of death on a sampling basis
throughout the country. This has not been done.
For example, in the case of cardiovascular dis-
eases, the National Heart Institute and investi-
gators in the cardiovascular field, suddenly a few
years ago, found themselves with a markedly
declining death rate from cardiovascular disease,
which has been going on since 1968, approxi-
mately 25%, over the time period 1968-77. Possi-
ble reasons for this decrease that were hypothe-
sized were that it was due to improved medical
care or to changes in risk factors, etc. Tb answer
one aspect requires knowledge concerning the
incidence rate of cardiovascular disease in the
United States. About 10 years ago a group pro-
posed that the National Heart Institute should,
on a sampling basis, determine the incidence rate
ofdifferent forms ofcardiovascular disease in the
United States. But there wasn't much interest in
doing that. Obviously if we had incidence data,
we would be able to evaluate the trend data much
better. I think it is a matter of looking at the
overall picture in terms ofdeciding what is neces-
sary for such a continuing surveillance; this has
not really been done.
The one thingthathashappened with regard to
utilizing death certificates for epidemiologic stud-
ies is to take care of the problems involved in
trying to obtain death certificates. As you know,
there are 50 states in the United States, and in
anykind ofresearch one has to contact each ofthe
states to obtain a copy of a death certificate.
About 10 or 15 years ago it was suggested that a
National Death Index be established to facilitate
obtaining of this information. In 1979, it was
supposed to have been set up but I understand
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that it did not become completely operative until
this year. I am not quite sure yet as to details of
its operation. Other efforts have been made. For
example, there was an effort made to have a
cooperative Federal/State health statistics sys-
tem. Five or six systems were established. They
were expensive, and I understand that that pro-
gram was finally dropped.
In contrast, in England there is a continuing
follow-up, which is much easier to utilize because
it has been integrated with the medical care/
national health service system. There is a central
place in England where all ofthe records, includ-
ing medical records of all of the general practi-
tioners, etc., are kept. If you want to follow up
people, youjust go ahead and follow them up.
Unfortunately, these things don't become ap-
parent until you do a study. In our recent study of
possible effects ofmicrowave exposure in our em-
bassy in Moscow, we were simply amazed thatthe
State Department didn't even know for a particu-
lar embassy the names of employees who had
been present in a particular year. One of our
recommendations was that they set up a system
ofcontinuingregistration ofthe employee popula-
tion which I think they have done.
DR. KASPERSON: Let me be clear about my ter-
minology. As I use the terms "risk avoidance"
versus "risk mitigation," I think of risk as com-
prising causal change that begins with the de-
ployment of a technology leading to exposure to
hazard and eventually to consequences ofvarious
kinds. I think of avoiding the risk as being an
interruption of that causal effect of the hazard
sometime prior to the registry of the conse-
quences. I think ofmitigation as being an amelio-
ration of the consequences after they have oc-
curred. Now, in the case ofrisk imposition where
I think the risk is being imposed upon people in a
less than voluntary way, one should always try
where possible to use risk avoidance rather than
risk mitigation.
Ihave aparticular case in minddrawnfrom the
area ofsocial risk, rather than health effects risk,
in locating energy facilities. The customary ap-
proach is to put down a major new energy facility
in some community, look at the fallout that oc-
curs, and then try to respond in various new
government programs to ameliorate the various
kinds ofharm that are registered in the commu-
nity. I think a much more reasonable process
would be to try to get the maximum amount of
risk avoidance in that situation rather than ame-
lioration ofthe consequences.
DR. DAVID V. BATES (Univ. British Columbia):
This is to Dr. Kasperson. Would you like to reflect
on the conditions where a choice of risk may be
permitted? I can think of these risk things only
with finite examples. Let us say that we know the
risk to a man starting exposure to asbestos at age
50 is very much less than ifhe starts exposure at
age 20, and you are faced with the question
whether a 20-year old requiring employment
should be allowed to choose the higher risk. An-
other example which I think is important, too, is
seatbelt legislation. In my Province of British
Columbia we have strict seatbelt legislation. And
is the question ofno choice affected, for instance,
by whether or not society is responsible for the
health care costs that derive from traffic acci-
dents? I would like to have your comment about
what are the facts that modify the question of
whether a choice should be permitted within a
given environment.
DR. KASPERSON: I think it is a difficult question.
First, I think seatbelts are a good example of a
situation or a risk where simply providing infor-
mation and trying to make the risk more volun-
tary is really not an acceptable solution. I agree
that the social price ofthe fatalities and injuries
that occur from automobile collisions affects the
decision, as a considerable part of that cost is
placed on society as a whole.
Similarly, I think in most kinds ofcatastrophic
risk there is substantial displacement in social
costs. The cases that are most suitable for provid-
ing information and trying to achieve the maxi-
mum degree of informed consent are those in
which the costs are internalized by the individual
in individual cases, or where regulatory solutions
perhaps involve such an inordinate cost to society
that proceeding through informed consent seems
to be the most reasonable manner. But I would
try to set up that kind of a continuum as indica-
tingthe direction in which one shouldtry to move
in a given case.
DR. LILIENFELD: Last year or early this year,
the issue of helmet legislation was raised in the
State of Maryland for motorcycle drivers. The
motorcyclists indicated that this was an individ-
ual choice on their part, with no particular influ-
ence on anybody else in society. However, it was
pointed out rather cogently in analyzing medical
care costs, when somebody riding a motorcycle
had an accident, it cost $5800, which was usually
paidby the state's Shock Trauma Unit or through
health insurance with a premium distributed
over the insured population, whereas ifthey wore
a helmet, the medical care costs of an accident
went down to $500. It seems to me rather difficult
to look at social costs. We cantalk aboutthem in a
general way, but itrequires much more data than
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is available and a much broader perspective than
is usually present.
On the otherhand, Dr. Kasperson has indicated
that one needs to provide full information; one
has to make sure that the risk-taker fully under-
stands what information is provided. What I don't
understand is how one can be sure when that
point is reached. Howdoyouknowwhenyouhave
full information and full understanding by risk-
takers? Individuals are intelligent, but nonethe-
less, there is a certain amount of scientific
knowhow often required, which most ofour popu-
lation do not have. It is a real problem.
DR. KASPERSON: I want to emphasize that the
state of informed consent that is required in ex-
periments with human subjects is generally real-
izable, in cases of most risks that are extant in
society. I think there are certain classes of risk
that the public intuitively tends to understand
much better than others. So I am much less con-
cerned, say, about falling off ladders, chainsaw
accidents or bicycle accidents as classes of risks
that might be described as relatively routine
events with acute consequences, than I am with
types of risk from high technology with severe
consequences, that I think are difficult for the
public to understand. I think one can work in the
direction oftrying to use as a norm principles of
informed consent, if that is the approach chosen
for distributing risk, but not with the expectation
that it will in fact be achieved. It probably is
much more suitable and realizable for some kinds
ofhazards than for others.
There is about a million dollars going into it
this year which is essentially being guaranteed
by the National Institutes ofHealth, and EPA is
also contributing. We expect by the end of a
second year of comparable funding, next year,
that the National Death Index will be a viable,
on-going entity which you can subscribe to in
order to get a very much better data set than
would be economically feasible than if you went
to each ofthe separate states.
DR. LEIGH KUTCHINSKY(Rocky Mountain Heal-
ing Arts Inst.): I have a lot ofproblems with the
word "choice" when one talks about assigned risk.
Choice to me has always meant that someone has
all of the available information and then acts
freely out of that information. Acceptable risk, I
think, is a misnomer because it implies a state of
knowledge.
What I would like to know from members ofthe
panel is: how well do models relate to projected
increases in information as new study techniques
become available? For example, a few years ago
the FDA lowered by 2500% the action level for
DDT in cow's milk. That change was in the period
ofone year. Thanks to Professor Allen's studies at
the University of Wisconsin, acceptable risks in
terms of PCBs were also lowered dramatically.
Now, in words that I can understand, meaning
simple nonbiochemical terms, what comfort can
people who were exposed to high levels under
previous "acceptable risk" numbers take from the
fact that all the necessary information wasn't
available, whether they gave free or implied con-
sent? How valid is the term "acceptable risk"
anyway for populations?
DR. HUNT I wanted to hark back to the com-
ment onthe Death Index. Even though some ofus
think part ofthe world is disintegrating in front
of our eyes, I don't think that part of it is. You
may recall the epidemiology community has been
very active for some years to impress upon those
inthe federal government responsible for funding
thatthe National Death Index was a cost effective
approach to improving some of the methods of
using epidemiology. Indeed, that funding is still
being allocated. The National Center for Health
Statistics has the responsibility in this.
DR. KASPERSON: I agreeto a considerable extent
with the position Dr. Kutchinsky took. I think
acceptable risk is to a considerable extent a mis-
nomer. I think it is helpful to think ofit as almost
an idealized state. Rather, most risks are simply
tolerated by the public, very often because they
don't get involved, or they have very little infor-
mation, or they are too busy with other things. So
acceptance in that sense is, I think, not realizable
for most kinds ofhazards, and I do think the term
is misleading. I do think, as I tried to argue, that
there are certain kinds ofrisks that permit one to
use acceptability strategies as a way of dealing
with the hazard. But ifyou consider a low expo-
sure hazard from multiple sources, connected
with chronic consequences, it is unlikely that the
public is going to be able to sort out that problem
to arrive at some kind of a reasonable decision
about whether they should accept the risk or not.
DR. LILIENFELD: The issue of acceptable risk,
although it is a term that I think most ofus like
to avoid, struck home to me a few years ago. I was
involved in the study ofa pesticide plant in Balti-
more in which we definitely demonstrated that
exposure to arsenic increased the lung cancer
death rate among the employees. When it came
down to the bottom line, the chemical company
decided to get out of the pesticide business and
closed down the plant. What amazed me was that
when the news media interviewed a number of
employees inthe plant, theseemployees indicated
thatthey wouldprefer to be employed even inthis
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contaminated plant with the attendant risks.
That is, the workers said outright thatthey would
rather have this risk than lose their jobs. One
interesting aspect occurred when we visited the
plant at one time. Even though the employees
knew what arsenic trioxide was and what its
adverse health effects were, they handled this
particular poison in a very nonchalant manner.
They literally threw the stuff around, even
though they were instructed to do otherwise.
This is a real problem, which occurs in many
situations. It happens when one tries to educate
people about cigarette smoking. Individuals are
willing to take the risk; as far as 20 years from
now is conceived, well, they won't worry about it.
I don't know how to handle such situations. I am
not quite sure that the social psychologists, those
in education, and those concerned with this gen-
eral problem have really been able to motivate
individuals to do things that may be in their best
interest.
DR. KUTCHINSKY: I understand the complexity
of the problem, but my question was not predi-
cated on the idea that we should protect people
from risks at all cost, rather that they be given
adequate and appropriate information, as well as
information that says this is what we know now
and that may very well change. I think there is a
greatdeal ofdifference inpeople opting to work in
a chemical plant, given certain information, and
the problem I have described. I don't really see
that it is appropriate to be their parent in saying
no, no, no, in all cases. But what about individ-
uals who freely choose exposure to something at a
few parts per million, believing they know what
the trade offs are, and then four or five years later
are told that new evidence indicates that the
acceptable risk level is now in terms ofexposures
to parts per billion?
What are the medical ethics of dealing with
that situation, and how often do we really tell
people that we can define risks in terms of the
state ofthe art, or state ofthe science only?
DR. LILIENFELD: Well, I agree. One ofthe prob-
lems is that you can only act in terms ofpresent
available scientific information. That is a real
problem. I was going to comment on this with
respect to the question Dr. Radford raised about
susceptible subgroups ofthe population. I person-
ally believe that there are susceptible subgroups,
although I might say there are those who do not
agree. For example, I think there are susceptible
subgroups with regard to cigarette smoking.
The problem we have is that we have very few
means available for identifying susceptible sub-
groups. Very little research has been done in this
area. Research ofthis kind is quite difficult, since
one ofthe limitations is in terms ofour scientific
knowledge and our scientific methodology. This
should be the ultimate objective in looking at risk
and doing something about it, because I think in
all situations, we have variations in susceptibil-
ity. All our biological knowledge tells us this. If
we can identify all the characteristics of individ-
ualssusceptible to exposuretodifferentchemicals
anddifferentenvironmental agents, we cansetup
a system, theoretically anyway, to screen these
individuals to decrease their exposure to a large
extent. ButIdon'tthinkwe candothis atpresent.
Ifone looks at the underlying biological models of
the disease, and particularly with respect to can-
cer, the underlying biological model is a multi-
stage model. That is, the general thinking is that
one is exposed to one hit now, one environmental
agent, that does something to a cell. Five years
from now another kind of exposure occurs that
has another effect. Then about 10 years later one
has another exposure. One may be an initiating
agent, which makes a transformation and then a
promoting agent is necessary to produce the ma-
lignancy.
Well, now, one of the problems is that in one
case there may be a virus and another, the agent
may be a chemical. In still another case it may be
ionizing radiation. In studying the situation, one
may not be able to find a relationship with one
specific exposure; it may be completely negative
in a study even of a million people. The findings
may be negative because in that specific agent
needs to interact with another agent to produce
the malignancy. An area that really has not been
studied sufficiently has been this whole issue of
interactions between exposures to different
agents and different kinds of agents. One of the
research areas that requires much work in the
next 10 years is increasing emphasis on the issue
of interaction between agents in terms of the
effect one is looking at. We know a bit more about
this with respect to cancer but I am willing to bet
that interaction exists with respect to most dis-
eases, including cardiovascular and other dis-
eases.
I think this issue relates definitely to animal
work and the limitations of animal studies, and
even pharmacokinetics, because they are looking
at the pharmacokinetics of a single agent, which
maybe very inadequate interms ofthe endresult
in which one is interested.
DIANE KIRTZ (Univ. Wisconsin): Dr. Kasperson
made the point about risk-bearers requiring full
access to information on risk in order to partici-
pate better in the decision-making process. I won-
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der what mechanism you and the other panel
members consider to be the most effective in dis-
seminating information, especially in cases
where there is uncertainty and dissension among
experts onthe magnitude ofrisk, and also in light
ofthe fact government publications may be sub-
ject to recall?
DR. DIETZ: That is a very difficult question to
answer. This same issue arose in another sympo-
sium discussion earlier this month at the 65th
Annual Meeting of The Federation of American
Societies for Experimental Biology in Atlanta,
and unfortunately no all-encompassing solutions
to this issue were reached there either. It seems
that we, as practicing toxicologists have a consid-
erable hurdle to overcome in attempting to com-
municate with the general public on a level that
they can both understand and relate to. Although
it requires concerted efforts on our parts, I think
it is ofmajor importance that we accomplish this
goal. Unfortunately, individuals that possess
both an understanding of our science and the
skills to communicate this knowledge to the gen-
eral public are in short supply. I am certainly not
one ofthese persons myself. However, Ithink that
until we manage to overcome this communicative
hurdle, it will continue to be an often frustrating
and difficult task for us to answer many of the
questions and concerns ofthe general public in an
adequate fashion. As Dr. Lilienfeld said, there are
no "elegant" solutions.
DR. HAROLD MARGULIES (U.S. Public Health
Service): You reminded me of the efforts once
made in Pakistan to explain more about malaria
to the people who lived there, to get them ac-
quainted with how it is transmitted. Among the
things done was a demonstration ofthe mosquito,
using a microscope. Later American advisors
went around andtalkedto some ofthe Punjabis to
see what they thought ofthe demonstration. The
conclusion they had come to was that in the
United States they have very large mosquitos.
Because I am a bureaucrat, I would like to pick
up all of this discussion and ask about process,
but one with which I am very seriously con-
cerned, and I would appreciate it if Vilma Hunt
would respond. This is a good panel and it has
demonstrated the problems, issues, difficulties in-
volved indemonstrating risk, and Ithinkthe bias
is clearly in favor of reduction of risk. We know
thatthe government andpoliticians will continue
to address that question, not at some time in the
future when the Death Index is up and running
for a decade, but right now. What should be the
relationship between people like yourselves, who
have scientific understanding (with all the limita-
tions) regarding risk assessment and perhaps of
risk control, and the decision process? To what
extent are you prepared, or should you be pre-
pared, to be involved in finite specific control
measures? Is the state of the science itself so
limited thatyou feel you should step aside and let
it be done entirely by a kind of "guess" process
dominating the political world?
DR. HUNMP The problem is complex. None of us
views a risk in the same way as another risk, at
the same time, or in looking at the same risk over
a period ofour lives. So that ifwe are attempting
to present information to the population of the
United States, very heterogeneous in the way
they perceive and use language and in the way
they assess their own personal risk, I think at-
tempting to get a formula to deal with this prob-
lem is not goingto lead us very far. I can feel I am
wallpapering myself in, in terms of whether one
can argue for a quantitative risk assessment or
not, if we are concerned with the issue of, let's
say, standard setting versus the choice ofan indi-
vidual on how he chooses to operate in his own
understanding ofrisk.
So I think we should be clear when we are
speaking on this issue as to whether we are talk-
ing about the specificity of standard-setting, and
how we choose to go through the mathematical
approach to providing a risk assessment that may
then be interpretable by some people, versus the
kind ofrisk assessment that isbeingprovidedto a
regulator so that they can make a judgment. I
thinkthe genetic counseling approach, which was
started many years ago, did develop a good per-
ception of how to describe to an individual what
the risk could be if he continued in a certain
course. I encountered this problem frequently in
having a call from apregnantwoman in adanger-
ous work environment, who said she had been
exposed to a high level of lead or ionizing radia-
tion. Should she have an abortion? I consider that
it was her choice to avoid a risk. I think we have
not adequately looked at that aspect in terms of
risk assessment.
What information is appropriate to give for a
person to avoid a risk? Does he have the right to
avoid the risk? In the workplace, that sometimes
is not the case, as we look atthe imminent hazard
clause. We had to go all the way through the
courts to decidewhetherthe workerhad a right to
avoid a risk. The point I would like to make in
considering the public policy issues ofrisk assess-
ment is that we must try to be specific as to
whether we are talking about the setting of the
standards for the public health at large or the
issue ofavoiding risk by particular individuals or
28DISCUSSION: SESSION I
sensitive people. I think we should keep in mind
that in any population, there is a range of sensi-
tivity within that population. Every single indi-
vidual in it has had a differing sensitivity
throughout its life cycle, be it the sperm or the
ovum originally, or the fertilized ovum, the fetus,
a 10-year old, a 20-year old, or in old age.
My question was to Dr. Lilienfeld, when you
mentioned the sensitivity inthe Utah study of10-
to 14-year olds, I wondered whether that was the
age of diagnosis or whether these were children
who had been exposed during an early period? I
raise that issuebecause I think more and more we
are coming to be concerned about the different
sensitivities in terms ofage, and whether indeed
this pre- and post-pubescent period is a sensitive
part ofthe life cycle.
DR. LILIENFELD: The 10 to 14 age group may
well be a more sensitive age group, but we really
don't know. This issue has come up with respect
to various other diseases. More research is neces-
sary.
DR. RADFORD: I am going to take the modera-
tor's prerogative to have the last word. One part
ofthe last question from the floor referred to the
role ofthe scientist in this process. Although Dr.
Kasperson touched on this to some extent, I want
to go onrecord as sayingthe role ofthe scientist is
to provide information, not to makejudgments as
to what are acceptable risks. I have to say this
because the history ofthe development ofoccupa-
tional exposure standards has been that in the
past, a self-appointed group of scientists has de-
cidedthattheywill be the onesto determine what
risks are acceptable. One ofthe changes that has
been occurring in the United States is that we
have abandoned this approach, although it still
exists in othercountries. Such decisions shouldbe
inthe hands ofthe elected officials ofthe public at
large, however good, bad or indifferent they may
be, to take the responsibility for the standards
applied, which implicitly is deciding the accept-
able level ofrisk. In other words, the question of
acceptability shouldbe in the political framework
where those deciding are responsible to the per-
sons regulated. But it certainly is not incumbent
upon the scientific community to be handing
down on tablets of stone what is an acceptable
risk to the worker or to the general public.
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